Liver health follow-up in type 2 diabetes
Part of Brain & nervous system, Heart & circulation, Hormones & metabolism, Lungs & breathing clinical trials.
This study follows up on people who already joined the EPSONIP trial to check how their liver health (MASLD) has changed over time. It uses MRI to look at the liver and does not test any new medicine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have taken part in the EPSONIP trial before.
- You must be 18 years or older.
- You must be able to have an MRI scan (no metal implants or claustrophobia issues).
- You cannot have other serious liver diseases (besides MASLD) that were found after the EPSONIP trial ended.
- You must not have had a liver transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a liver stiffness measurement to a lifestyle program helps people with MASLD (a type of fatty liver disease) improve their liver health. It is designed for people who have fatty liver and at least one sign of metabolic syndrome, like high blood pressure or diabetes.
This study screens people who are overweight or have metabolic risks (like high blood pressure, high cholesterol, or prediabetes) to check for early liver problems. It uses simple blood tests and an ultrasound to look at your liver health.
This research studies fatty liver disease linked to metabolic problems like diabetes and obesity. You'll wear a fitness tracker and have liver imaging to help doctors understand the disease and find new treatments.
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This study is looking for people with type 2 diabetes and fatty liver disease to find better ways to track how the disease progresses. They will use special tests (biomarkers) to see if the liver is getting worse over time.
Hear when a new Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.